"eventual capillary and arteriolar occlusion due to the development of plexiform lesions and necrotising arteritis."
"The phenomenon was first described by Victor Eisenmenger (1864-1932) an Austrian physician from Vienna in 1897, in a 32-year-old patient with a large VSD, but his name was only associated with the syndrome in 1958 6,7."
"Some pharmacological agents show the prospect of being beneficial in pulmonary arterial hypertension, including Eisenmenger syndrome (see PAH article). In selected cases combined heart and lung transplantation can be performed."
Expected headings
"Complications"